Reversal of multidrug resistance by magnetic chitosan-Fe₃O₄ nanoparticle-encapsulated MDR1 siRNA in glioblastoma cell line

References

• Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al.. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683–710.
   PubMed Web of Science ®Google Scholar
• Rosenfeld MR, Pruitt AA. Management of malignant gliomas and primary CNS lymphoma: standard of care and future directions. Continuum (Minneap Minn). 2012;18:406–15.
   PubMedGoogle Scholar
• Tews D S, Nissen A, Kulgen C, Gaumann AK. Drug resistance-associated factors in primary and secondary glioblastomas and their pre-cursor tumors. J Neurooncol. 2000;50:227–37.
   PubMed Web of Science ®Google Scholar
• Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004;25:423–9.
   PubMed Web of Science ®Google Scholar
• Shirasaka Y, Onishi Y, Sakurai A, Nakagawa H, Ishikawa T, Yamashita S. Evaluation of human P-glycoprotein (MDR1/ABCB1) ATPase activity assay method by comparing with in vitro transport measurements: Michaelis-Menten kinetic analysis to estimate the affinity of P-glycoprotein to drugs. Biol Pharm Bull. 2006;29:2465–71.
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhang Y, Sun M, He Y. Reversion of multidrug resistance in human glioma by RNA interference. Neurol Res. 2008;30:562–6.
   PubMed Web of Science ®Google Scholar
• Dykxhoorn DM. RNA interference as an anticancer therapy: a patent perspective. Expert Opin Ther Pat. 2009;19:475–91.
   PubMed Web of Science ®Google Scholar
• Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011;11:59–67.
   PubMed Web of Science ®Google Scholar
• Moore CB, Guthrie EH, Huang MT, Taxman DJ. Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. Methods Mol Biol. 2010;629:141–58.
   PubMedGoogle Scholar
• Hamasaki T, Suzuki H, Shirohzu H, Matsumoto T, D’Alessandro-Gabazza CN, Gil-Bernabe P, et al.. Efficacy of a novel class of RNA interference therapeutic agents. PLoS One. 2012;7:e42655.
   PubMed Web of Science ®Google Scholar
• Schäfer J, Höbel S, Bakowsky U, Aigner A. Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials. 2010;31:6892–900.
   PubMed Web of Science ®Google Scholar
• Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA. Nanotechnology-based approaches in anticancer research. Int J Nanomedicine. 2012;7:4391–408.
   PubMed Web of Science ®Google Scholar
• Luo X, Song X, Zhu A, Si Y, Ji L, Ma Z, et al.. Development of poly(vinyl acetate-methylacrylic acid)/chitosan/Fe3O4 nanoparticles for the diagnosis of non-alcoholic steatohepatitis with magnetic resonance imaging. J Mater Sci Mater Med. 2012;23:3075–82.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001,25:402–8.
   PubMed Web of Science ®Google Scholar
• Schuldes H, Dolderer JH, Zimmer G, Knobloch J, Bickeböller R, Jonas D, et al.. Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts. Eur J Cancer. 2001;37:660–7.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58.
   PubMed Web of Science ®Google Scholar
• Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2010;31:358–65.
   PubMed Web of Science ®Google Scholar
• Chen BA, Sun Q, Wang XM, Gao F, Dai Y, Yin Y, et al.. Reversal in multidrug resistance by magnetic nanoparticle of Fe3O4 loaded with adriamycin and tetrandrine in K562/AO2 leukemic cells. Int J Nanomed. 2008;3:277–86.
   PubMed Web of Science ®Google Scholar
• Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al.. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900–8.
   PubMed Web of Science ®Google Scholar
• Park SG, Jung S, Ryu HH, Jung TY, Moon KS, Kim IY, et al.. Role of 14-3-3-beta in the migration and invasion in human malignant glioma cell line U87MG. Neurol Res. 2012;3:893–900.
   Web of Science ®Google Scholar
• Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1:97–117.
   PubMed Web of Science ®Google Scholar
• Hao YX, He ZW, Zhu JH, Shen Q, Sun JZ, Du N, et al.. Reversal of multidrug resistance in renal cell carcinoma by short hairpin RNA targeting MDR1 gene. Chin Med J (Engl). 2012;125:2741–5.
   PubMed Web of Science ®Google Scholar
• Garrigues A, Nugier J, Orlowski S, Ezan E. A High-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Analytical Biochemistry. 2002;305:106–14.
   PubMed Web of Science ®Google Scholar
• Lin W, Zhang J, Zhang J, Liu X, Fei Z, Li X, et al.. RNAi-mediated inhibition of MSP58 decreases tumour growth, migration and invasion in a human glioma cell line. J Cell Mol Med. 2009;13:4608–22.
   PubMed Web of Science ®Google Scholar
• Valera ET, Lucio-Eterovic AK, Neder L, Scrideli CA, Machado HR, Carlotti-Junior CG, et al.. Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system. J Neurooncol. 2007;85:1–10.
   PubMed Web of Science ®Google Scholar
• Gondi CS, Talluri L, Dinh DH, Gujrati M, Rao JS. RNAi-mediated downregulation of MMP-2 activates the extrinsic apoptotic pathway in human glioma xenograftcells. Int J Oncol. 2009;35:851–9.
   PubMed Web of Science ®Google Scholar
• de Verdière AC, Dubernet C, Némati F, Soma E, Appel M, Ferté J, et al.. Reversion of multidrug resistance with polyalkylcyanoacryate nanoparticles: towards a mechanism of action. Br J Cancer. 1997;76:198–205.
   PubMed Web of Science ®Google Scholar
• Dönmez Yaprak, Gündüz Ufuk. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed Pharmacother. 2011;65:85–9.
   PubMed Web of Science ®Google Scholar